Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders. Shares of the cardiovascular biotech company are skyrocketing 213%, through afternoon trading on Monday, April 17, 2023. Over the past three months, Windtree Therapeutics has seen an average daily volume of 147,720 shares. However, a volume of 4.15 million shares, or a dollar volume of around $62.08 million, has already exchanged hands through afternoon trading.
Shares of Windtree Therapeutics are surging after the company announced it has been granted Patent No. 3599243 by the European Patent Office. This patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” grants protection until July 2038. The patent covers the revolutionary SERCA2a Activator class of drugs, which have dual mechanisms of action – they inhibit the Na+/K+ pump and activate SERCA2a, in addition to offering pure SERCA2a activators.
The SERCA2a enzyme, which is decreased in heart failure, has presented an opportunity for potential therapeutic advancement. Windtree’s strategy of dual-mechanism compounds, with istaroxime as its lead candidate for heart failure and cardiogenic shock treatment, is aiming to take advantage of this exciting chance.
Dual mechanism compounds are developed to provide both oral and intravenous therapies for heart failure treatment, whether it be an inpatient hospital stay for an acute case or an outpatient oral treatment for a chronic one.
Windtree Therapeutics is forging a multi-asset empire, centered around compounds with the capability to trigger SERCA2a. As part of its heart failure platform, they are also actively pursuing follow-up oral pre-clinical SERCA2a activator assets. Beyond istaroxime, Windtree boasts rostafuroxin, a novel, specifically designed medication targeting hypertensive patients with certain genetic profiles.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/